使用VAECMO病例报告治疗临近心脏骤停的登革热心肌炎患者
Vipul Bansal1, Vivek Gupta1, Naved Aslam1
1Hero DMC Heart Institute, Ludhiana, Punjab, India.
The International journal of artificial organs
|August 25, 2025
概括
这项案例研究突出显示,在患有登革热休克综合征,假体门和严重心脏功能障碍的致病肥胖患者中,静脉外膜氧化 (VA ECMO) 的成功管理. 它详细介绍了复杂病例的重症监护方面的挑战.
科学领域:
- 心脏病学
- 重症监护医疗
- 传染性疾病
背景情况:
- 登革热休克综合征可能会导致严重的心脏并发症,包括心肌功能障碍和恶性心律失常.
- 假心患者在重症监护机构面临独特的挑战,尤其是在严重的全身性疾病期间.
- 由于生理变化和器官功能障碍的风险增加,致病性肥胖症进一步使治疗复杂化.
研究的目的:
- 描述使用VA ECMO成功治疗严重心脏功能障碍和假发的复杂登革热休克综合征.
- 突出VA ECMO在患有先前并发症和假肢器件的患者中所面临的挑战和考虑因素.
- 讨论VA ECMO和持续置换疗法 (CRRT) 在严重登革热期间支持多器官功能障碍的作用.
主要方法:
- 一名45岁的肥胖男性患有甲状腺膜假体,患有登革热休克综合征,心室失常和多器官功能障碍.
- 心声检查显示严重的左心室功能障碍 (LVEF 8% - 10%),没有假并发症.
- 用Oxiris过器进行静脉ECMO和CRRT治疗,以治疗耐火性心律失常,急性损伤和肝功能障碍.
主要成果:
- 通过VA ECMO支持,该患者的血液动力学稳定和恢复取得了成功.
- 使用Oxiris过器的连续置换疗法有助于治疗急性损伤和肝功能障碍.
- 尽管假发门和心肌功能障碍带来了挑战,但VA ECMO提供了至关重要的循环和呼吸支持.
结论:
- 在患有严重心脏功能障碍和多器官衰竭的登革热休克综合征的患者中,VA ECMO可以成为拯救生命的干预措施.
- 在ECMO治疗期间,仔细选择和管理患者至关重要,以克服与假体门和先前存在的疾病相关的挑战.
- 这一案例强调了先进的机械循环支持在治疗复杂并发性疾病中的重要性.
相关概念视频
01:30Cardiomyopathy II: Dilated Cardiomyopathy
22
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
22
01:14Myocarditis III: Medical Management
15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
01:29Cardiomyopathy V: Interprofessional Care
33
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
33
01:26Mitral Stenosis III: Medical Management
21
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
21
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:25Mitral Regurgitation III: Medical Management
30
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
30